IXHL vs. NRIX, COGT, AUPH, PAHC, WVE, NUVB, TNGX, STOK, LBPH, and GHRS
Should you be buying Incannex Healthcare stock or one of its competitors? The main competitors of Incannex Healthcare include Nurix Therapeutics (NRIX), Cogent Biosciences (COGT), Aurinia Pharmaceuticals (AUPH), Phibro Animal Health (PAHC), Wave Life Sciences (WVE), Nuvation Bio (NUVB), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Longboard Pharmaceuticals (LBPH), and GH Research (GHRS). These companies are all part of the "pharmaceutical preparations" industry.
Incannex Healthcare (NASDAQ:IXHL) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
Incannex Healthcare has a beta of 8.65, indicating that its stock price is 765% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.
In the previous week, Nurix Therapeutics had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 6 mentions for Nurix Therapeutics and 4 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.96 beat Nurix Therapeutics' score of 0.75 indicating that Incannex Healthcare is being referred to more favorably in the media.
Incannex Healthcare has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -178.93%. Incannex Healthcare's return on equity of 0.00% beat Nurix Therapeutics' return on equity.
Nurix Therapeutics has a consensus target price of $21.88, indicating a potential upside of 38.89%. Given Nurix Therapeutics' higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Incannex Healthcare.
0.4% of Incannex Healthcare shares are owned by institutional investors. 14.6% of Incannex Healthcare shares are owned by company insiders. Comparatively, 7.2% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Nurix Therapeutics received 50 more outperform votes than Incannex Healthcare when rated by MarketBeat users.
Incannex Healthcare has higher earnings, but lower revenue than Nurix Therapeutics.
Summary
Incannex Healthcare beats Nurix Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Incannex Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Incannex Healthcare Competitors List
Related Companies and Tools
